Skip to main content
. 2015 Oct 13;59(11):6922–6929. doi: 10.1128/AAC.01390-15

FIG 1.

FIG 1

Prevalence of specific amino acid substitutions at established NS5A resistance loci detected by population sequencing after monotherapy with elbasvir in the phase 1b study. The column graph displays the most common postbaseline variants identified in patients infected with genotype (GT) 1a, 1b, or 3 in the phase 1b study. Among the polymorphisms examined, substitutions at amino acids 28, 30, 31, and 93 were each observed in more than 10% of evaluable patients.